Gait changes following botulinum toxin A treatment in stroke

Top Stroke Rehabil. 2009 Sep-Oct;16(5):367-76. doi: 10.1310/tsr1605-367.

Abstract

Purpose: To characterize the effects of botulinum toxin A treatment of spastic plantar flexors in stroke on joint mobility and gait kinematics and kinetics.

Method: Nine patients with hemiparetic stroke presenting with ankle hypertonicity participated in this exploratory open-label case series study. Comprehensive gait analysis provided bilateral kinematic and kinetic information for the ankle, knee, and hip joints throughout the stance phase. Data were obtained at baseline, 2 weeks, and 10 weeks post botulinum toxin injection of the spastic plantar flexors.

Results: Passive ankle range of motion increased post injection (p < .05). The amount of plantarflexion in late stance was significantly reduced (p < .05) while the maximum dorsiflexion increased in midstance at 10 weeks post treatment. The angular displacement profiles for the knee revealed that patients tended to display less hyperextension following treatment (p = .053). No significant changes in kinetic measures were found; however, case-by-case observations suggested that most patients experienced improvements in positive work production.

Conclusions: The findings indicate that botulinum toxin treatment results in improved joint mobility and ankle kinematics and, in some patients, increases in positive work, suggesting better gait performance.

Publication types

  • Clinical Conference
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Ankle Joint / physiopathology
  • Biomechanical Phenomena / drug effects
  • Biomechanical Phenomena / physiology
  • Botulinum Toxins, Type A / pharmacology*
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Follow-Up Studies
  • Gait / drug effects*
  • Hip Joint
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / pharmacology*
  • Neuromuscular Agents / therapeutic use*
  • Range of Motion, Articular
  • Stroke / drug therapy*
  • Stroke / physiopathology*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A